A detailed history of Citigroup Inc transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Citigroup Inc holds 49,594 shares of DCTH stock, worth $595,623. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,594
Holding current value
$595,623
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.36 - $11.0 $365,011 - $545,534
49,594 New
49,594 $447,000

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $103M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.